Is NEUP or GANX more profitable?

Neuphoria Therapeutics' return on equity of -38.31% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -38.31% -28.92% Gain Therapeutics N/A -161.59% -118.36%

Does the media refer more to NEUP or GANX?

In the previous week, Gain Therapeutics had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 4 mentions for Gain Therapeutics and 3 mentions for Neuphoria Therapeutics. Gain Therapeutics' average media sentiment score of 0.43 beat Neuphoria Therapeutics' score of 0.33 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GUTS or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -38.31% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Neuphoria Therapeutics N/A -38.31% -28.92%

Does the media prefer GUTS or NEUP?

In the previous week, Fractyl Health had 14 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 17 mentions for Fractyl Health and 3 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.33 beat Fractyl Health's score of 0.01 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 1 Very Positive mention(s) 0 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NEUP or IBIO more profitable?

Neuphoria Therapeutics' return on equity of -38.31% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -38.31% -28.92% iBio N/A -40.66% -35.78%

Does the media refer more to NEUP or IBIO?

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 3 articles in the media. Neuphoria Therapeutics' average media sentiment score of 0.33 beat iBio's score of 0.26 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, NEUP or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Neuphoria Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuphoria Therapeutics $1.17M 16.05 -$13.45M -$6.22 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is NEUP or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -38.31% -28.92% OKYO Pharma N/A N/A N/A

Does the media favor NEUP or OKYO?

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 2 mentions for OKYO Pharma. Neuphoria Therapeutics' average media sentiment score of 0.33 beat OKYO Pharma's score of 0.00 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NEUP or PMVP more profitable?

Neuphoria Therapeutics' return on equity of -38.31% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -38.31% -28.92% PMV Pharmaceuticals N/A -78.11% -70.13%

Does the media refer more to NEUP or PMVP?

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 2 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.51 beat Neuphoria Therapeutics' score of 0.33 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PMV Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neuphoria Therapeutics (NEUP) Competitors

$3.47 -0.04 (-1.14%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$3.46 -0.01 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

Compare

NEUP vs. GANX, GUTS, IBIO, OKYO, and PMVP

Should you buy Neuphoria Therapeutics stock or one of its competitors? Neuphoria Therapeutics's main competitors and comparable companies include Gain Therapeutics (GANX), Fractyl Health (GUTS), iBio (IBIO), OKYO Pharma (OKYO), and PMV Pharmaceuticals (PMVP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Neuphoria Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17M	16.05	-$13.45M	-$6.22	N/A
Gain Therapeutics	$50K	1,492.49	-$20.16M	-$0.50	N/A

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 1.6% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neuphoria Therapeutics' return on equity of -38.31% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Gain Therapeutics	N/A	-161.59%	-118.36%

In the previous week, Gain Therapeutics had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 4 mentions for Gain Therapeutics and 3 mentions for Neuphoria Therapeutics. Gain Therapeutics' average media sentiment score of 0.43 beat Neuphoria Therapeutics' score of 0.33 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuphoria Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 101.73%. Gain Therapeutics has a consensus target price of $7.50, indicating a potential upside of 338.60%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

Gain Therapeutics beats Neuphoria Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Fractyl Health had 14 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 17 mentions for Fractyl Health and 3 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.33 beat Fractyl Health's score of 0.01 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	1 Very Positive mention(s)	0 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuphoria Therapeutics' return on equity of -38.31% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Neuphoria Therapeutics	N/A	-38.31%	-28.92%

Fractyl Health presently has a consensus target price of $5.50, suggesting a potential upside of 1,252.68%. Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 101.73%. Given Fractyl Health's stronger consensus rating and higher possible upside, research analysts plainly believe Fractyl Health is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 8.4% of Fractyl Health shares are owned by company insiders. Comparatively, 1.6% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Fractyl Health has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than Fractyl Health. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	719.14	-$140.95M	-$0.88	N/A
Neuphoria Therapeutics	$1.17M	16.05	-$13.45M	-$6.22	N/A

Summary

Fractyl Health beats Neuphoria Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to iBio?

Neuphoria Therapeutics (NASDAQ:NEUP) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 3 articles in the media. Neuphoria Therapeutics' average media sentiment score of 0.33 beat iBio's score of 0.26 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Neuphoria Therapeutics' return on equity of -38.31% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
iBio	N/A	-40.66%	-35.78%

Neuphoria Therapeutics has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17M	16.05	-$13.45M	-$6.22	N/A
iBio	$100K	723.49	-$33.04M	-$0.34	N/A

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.6% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 1.6% of iBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 101.73%. iBio has a consensus target price of $5.29, indicating a potential upside of 369.84%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
iBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Summary

Neuphoria Therapeutics and iBio tied by winning 7 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to OKYO Pharma?

Neuphoria Therapeutics (NASDAQ:NEUP) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

OKYO Pharma has lower revenue, but higher earnings than Neuphoria Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17M	16.05	-$13.45M	-$6.22	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.6% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Neuphoria Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 101.73%. OKYO Pharma has a consensus target price of $5.67, indicating a potential upside of 285.49%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 2 mentions for OKYO Pharma. Neuphoria Therapeutics' average media sentiment score of 0.33 beat OKYO Pharma's score of 0.00 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OKYO Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OKYO Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
OKYO Pharma	N/A	N/A	N/A

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market.

Summary

OKYO Pharma beats Neuphoria Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to PMV Pharmaceuticals?

Neuphoria Therapeutics (NASDAQ:NEUP) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Neuphoria Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17M	16.05	-$13.45M	-$6.22	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 1.6% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Neuphoria Therapeutics and 2 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.51 beat Neuphoria Therapeutics' score of 0.33 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PMV Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuphoria Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 101.73%. PMV Pharmaceuticals has a consensus price target of $4.33, indicating a potential upside of 142.09%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Neuphoria Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Neuphoria Therapeutics' return on equity of -38.31% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

Summary

PMV Pharmaceuticals beats Neuphoria Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEUP vs. The Competition

Export

Metric	Neuphoria Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.78M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-0.56	13.06	275.66	26.04
Price / Sales	16.05	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.76	16.63	10.93	6.31
Net Income	-$13.45M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-4.67%	-2.99%	-2.00%	-1.66%
1 Month Performance	-7.96%	-10.81%	-6.19%	-4.68%
1 Year Performance	-82.17%	19.19%	8.03%	1.57%

Neuphoria Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEUP Neuphoria Therapeutics	2.4685 of 5 stars	$3.47 -1.1%	$7.00 +101.7%	-82.2%	$18.78M	$1.17M	N/A	8	Upcoming Earnings
GANX Gain Therapeutics	1.9574 of 5 stars	$1.78 -3.3%	$7.50 +321.3%	-10.9%	$77.69M	N/A	N/A	21	Positive News
GUTS Fractyl Health	2.3351 of 5 stars	$0.49 +3.3%	$5.50 +1,032.6%	-73.8%	$77.30M	$90K	N/A	73	Trending News
IBIO iBio	2.8718 of 5 stars	$1.19 -0.8%	$5.29 +344.2%	N/A	$76.53M	$100K	N/A	23
OKYO OKYO Pharma	2.1818 of 5 stars	$1.38 flat	$5.67 +310.6%	-28.3%	$72.42M	N/A	N/A	5	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEUP) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. GANX, GUTS, IBIO, OKYO, and PMVP

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Summary

How does Neuphoria Therapeutics compare to Fractyl Health?

Summary

How does Neuphoria Therapeutics compare to iBio?

Summary

How does Neuphoria Therapeutics compare to OKYO Pharma?

Summary

How does Neuphoria Therapeutics compare to PMV Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuphoria Therapeutics (NEUP) Competitors

NEUP vs. GANX, GUTS, IBIO, OKYO, and PMVP

How does Neuphoria Therapeutics compare to Gain Therapeutics?

Which has higher earnings & valuation, NEUP or GANX?

Do institutionals and insiders believe in NEUP or GANX?

Is NEUP or GANX more profitable?

Does the media refer more to NEUP or GANX?

Do analysts prefer NEUP or GANX?

Which has more volatility & risk, NEUP or GANX?

Summary

How does Neuphoria Therapeutics compare to Fractyl Health?

Does the media prefer GUTS or NEUP?

Is GUTS or NEUP more profitable?

Do analysts recommend GUTS or NEUP?

Do insiders & institutionals hold more shares of GUTS or NEUP?

Which has more volatility & risk, GUTS or NEUP?

Which has stronger valuation and earnings, GUTS or NEUP?

Summary

How does Neuphoria Therapeutics compare to iBio?

Does the media refer more to NEUP or IBIO?

Which has more risk & volatility, NEUP or IBIO?

Is NEUP or IBIO more profitable?

Which has higher valuation & earnings, NEUP or IBIO?

Do insiders and institutionals believe in NEUP or IBIO?

Do analysts rate NEUP or IBIO?

Summary

How does Neuphoria Therapeutics compare to OKYO Pharma?

Which has better valuation and earnings, NEUP or OKYO?

Do institutionals & insiders believe in NEUP or OKYO?

Do analysts rate NEUP or OKYO?

Does the media favor NEUP or OKYO?

Is NEUP or OKYO more profitable?

Which has more risk and volatility, NEUP or OKYO?

Summary

How does Neuphoria Therapeutics compare to PMV Pharmaceuticals?

Which has better earnings and valuation, NEUP or PMVP?

Do institutionals & insiders have more ownership in NEUP or PMVP?

Does the media refer more to NEUP or PMVP?

Do analysts rate NEUP or PMVP?

Which has more volatility and risk, NEUP or PMVP?

Is NEUP or PMVP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP vs. The Competition

Neuphoria Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools